{"organizations": [], "uuid": "314528f7484f6be915811e41db4f3b746917f535", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-seattle-genetics-reports-q1-loss-p/brief-seattle-genetics-reports-q1-loss-per-share-of-0-73-idUSASC09XUF", "country": "US", "domain_rank": 408, "title": "BRIEF-Seattle Genetics Reports Q1 Loss Per Share Of $0.73", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-26T23:12:00.000+03:00", "replies_count": 0, "uuid": "314528f7484f6be915811e41db4f3b746917f535"}, "author": "", "url": "https://www.reuters.com/article/brief-seattle-genetics-reports-q1-loss-p/brief-seattle-genetics-reports-q1-loss-per-share-of-0-73-idUSASC09XUF", "ord_in_thread": 0, "title": "BRIEF-Seattle Genetics Reports Q1 Loss Per Share Of $0.73", "locations": [], "entities": {"persons": [], "locations": [{"name": "seattle", "sentiment": "none"}], "organizations": [{"name": "brief-seattle genetics reports", "sentiment": "negative"}, {"name": "seattle genetics inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 26 (Reuters) - Seattle Genetics Inc:\n* SEATTLE GENETICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS\n* Q1 LOSS PER SHARE $0.73 * Q1 REVENUE $140.6 MILLION VERSUS I/B/E/S VIEW $119.7 MILLION\n* Q1 EARNINGS PER SHARE VIEW $-0.41 â€” THOMSON REUTERS I/B/E/S\n* FOR Q2 OF 2018, SEATTLE GENETICS EXPECTS SALES OF ADCETRIS WILL BE IN RANGE OF $105 MILLION TO $110 MILLION\n* SEES 2018 RESEARCH AND DEVELOPMENT (RESEARCH AND DEVELOPMENT) $530 MILLION TO $580 MILLION\n* SEES 2018 SELLING, GENERAL AND ADMINISTRATION (SG&A) $220 MILLION TO $240 MILLION\n* SEES 2018 NON-CASH COSTS $95 MILLION TO $105 MILLION\n* ECHELON-2 DATA EXPECTED IN 2018 Source text for Eikon: (Reuters.Briefs@thomsonreuters.com)\n ", "external_links": [], "published": "2018-04-26T23:12:00.000+03:00", "crawled": "2018-04-26T23:34:49.003+03:00", "highlightTitle": ""}